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Summary
Background Patients admitted to hospital can acquire multidrug-resistant organisms and Clostridium diffi  cile from 
inadequately disinfected environmental surfaces. We determined the eff ect of three enhanced strategies for terminal 
room disinfection (disinfection of a room between occupying patients) on acquisition and infection due to meticillin-
resistant Staphylococcus aureus, vancomycin-resistant enterococci, C diffi  cile, and multidrug-resistant Acinetobacter.
Methods We did a pragmatic, cluster-randomised, crossover trial at nine hospitals in the southeastern USA. Rooms 
from which a patient with infection or colonisation with a target organism was discharged were terminally disinfected 
with one of four strategies: reference (quaternary ammonium disinfectant except for C diffi  cile, for which bleach was 
used); UV (quaternary ammonium disinfectant and disinfecting ultraviolet [UV-C] light except for C diffi  cile, for which 
bleach and UV-C were used); bleach; and bleach and UV-C. The next patient admitted to the targeted room was 
considered exposed. Every strategy was used at each hospital in four consecutive 7-month periods. We randomly 
assigned the sequence of strategies for each hospital (1:1:1:1). The primary outcomes were the incidence of infection or 
colonisation with all target organisms among exposed patients and the incidence of C diffi  cile infection among exposed 
patients in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT01579370.
Findings 31 226 patients were exposed; 21 395 (69%) met all inclusion criteria, including 4916 in the reference group, 
5178 in the UV group, 5438 in the bleach group, and 5863 in the bleach and UV group. 115 patients had the primary 
outcome during 22 426 exposure days in the reference group (51·3 per 10 000 exposure days). The incidence of target 
organisms among exposed patients was signifi cantly lower after adding UV to standard cleaning strategies (n=76; 
33·9 cases per 10 000 exposure days; relative risk [RR] 0·70, 95% CI 0·50–0·98; p=0·036). The primary outcome was 
not statistically lower with bleach (n=101; 41·6 cases per 10 000 exposure days; RR 0·85, 95% CI 0·69–1·04; p=0·116), 
or bleach and UV (n=131; 45·6 cases per 10 000 exposure days; RR 0·91, 95% CI 0·76–1·09; p=0·303) among exposed 
patients. Similarly, the incidence of C diffi  cile infection among exposed patients was not changed after adding UV to 
cleaning with bleach (n=38 vs 36; 30·4 cases vs 31·6 cases per 10 000 exposure days; RR 1·0, 95% CI 0·57–1·75; 
p=0·997).
Interpretation A contaminated health-care environment is an important source for acquisition of pathogens; enhanced 
terminal room disinfection decreases this risk.
Funding US Centers for Disease Control and Prevention.
 Introduction
Multidrug-resistant organisms and Clostridium diffi  cile 
are common causes of health-care-associated infections 
that lead to adverse patient outcomes.1 The hospital 
environ ment may be an important source for trans-
mission of these organisms. First, hospitals are con-
taminated with clinically important multidrug-resistant 
organisms and C diffi  cile.2 Meticillin-resistant Staphyl-
ococcus aureus (MRSA), vancomycin-resistant enterococci 
(VRE), and Acinetobacter spp can survive on inanimate 
surfaces for days, and C diffi  cile can survive for months.3 
Second, only 50% of surfaces in hospital rooms are 
suffi  ciently cleaned between patient stays.4 As a result, 
patients admitted to rooms previously occupied by 
patients with multidrug-resistant organisms and 
C diffi  cile are at an increased risk of subsequent infection 
or colonisation with these organisms.5 Finally, the 
contaminated environment is an important source of 
health-care personnel hand contamination.6–8
Terminal room disinfection (disinfection of a room 
between occupying patients) can be enhanced by using a 
chemical disinfectant with sporicidal activity or by use of 
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supplemental disinfection technologies. However, to our 
knowledge, no multicentre randomised assessment of 
enhanced terminal room disinfection strategies has been 
done.9 We designed the Benefi ts of Enhanced Terminal 
Room Disinfection study to assess the eff ects of four 
diff erent strategies for terminal room disinfection on 
acquisition of multidrug-resistant organisms and 
C diffi  cile.
Methods
Study design and participants
We did this pragmatic, multicentre, cluster-randomised, 
crossover trial in nine hospitals in the USA from 
April, 2012, to July, 2014 (appendix). We tested one of four 
strategies for terminal room disinfection. Three strategies 
included enhanced terminal disinfection, and one 
included the standard terminal disinfection.
These four strategies were used in targeted rooms, 
defi ned as single-patient rooms from which a patient on 
contact precautions was discharged or transferred. In the 
reference group, targeted rooms were disinfected with 
quaternary ammonium-containing disinfectant for all 
rooms except those with patients with C diffi  cile, in which 
a hypochlorite-containing disinfectant (bleach) was used. 
In the UV group, targeted rooms were disinfected with 
quaternary ammonium-containing disinfectant and a 
UV-C device except rooms of patients with C diffi  cile, in 
which a bleach-containing disinfectant and UV-C device 
were used. In the bleach group, a bleach-containing dis-
infectant was used in all targeted rooms. In the bleach 
and UV group, a bleach-containing disinfectant and a 
UV-C device were used for all targeted rooms.
Each strategy was used at every study hospital for four 
consecutive 7-month study periods. Each study period 
consisted of a 1-month wash-in period followed by a 
6-month period of data collection. The sequence of
disinfection strategies was randomly selected for each 
hospital.
We selected study hospitals to include multiple types of 
hospitals (tertiary, community, Veterans Aff airs) as a 
convenience sample. All microbiological cultures were 
considered for inclusion in our outcomes. Cultures may 
have been representative of infection or colonisation and 
included surveillance cultures, if obtained by policy at 
the study hospital. No screening cultures were obtained 
specifi cally for the study.
The Duke University Health System Institutional Review 
Board served as the central institutional review board. We 
received a waiver of informed consent for this study.
Randomisation and masking
We did resource-dependent randomisation of hospitals, 
taking into account the number of UV devices available 
(nine). First, we used a random number generator to 
determine the order in which hospitals would be 
randomly assigned a disinfection strategy. Then, we used 
a random number generator to determine the order in 
which disinfection strategies were used in each hospital. 
We continued this process for each hospital but counted 
the number of machines already assigned for other 
hospitals in each study period. If all nine UV-C devices 
were already assigned for a period, subsequent hospitals 
could not be assigned to one of the UV strategies for that 
period. Ultimately, all hospitals used all four strategies in 
a 1:1:1:1 ratio (appendix p 9).  Allocation was not masked. 
Procedures
All hospitals used gown and glove precautions 
(ie, contact precautions) for patients known or suspected 
to harbour multidrug-resistant organisms or C diffi  cile. 
Environ men tal services personnel were trained on 
the appropriate use of the disinfectants, cleaning 
Research in context
Evidence before this study
The hospital environment is contaminated with 
multidrug-resistant organisms and Clostridium diffi  cile and is 
often disinfected inadequately. As a result, patients who enter 
contaminated hospital rooms are at increased risk for 
acquisition and infection from these organisms. Enhanced 
disinfection strategies may decrease the risk for transmission of 
such bacteria through the hospital environment, but supportive 
evidence is limited to single centre or quasi-experimental 
studies. According to a systematic review by Han and 
colleagues, no randomised multicentre trials have been done to 
determine the effi  cacy of enhanced strategies.
Added value of this study
Our study is, to our knowledge, the fi rst multicentre 
randomised controlled trial to evaluate the eff ect of enhanced 
disinfection strategies on acquisition and infection due to four 
target organisms (meticillin-resistant Staphylococcus aureus, 
vancomycin-resistant staphylococci, multidrug-resistant 
Acinetobacter, and C diffi  cile). Adding a UV-C device to 
quaternary ammonium disinfection decreased the risk of 
subsequent acquisition and infection by target organisms. 
Our study shows the effi  cacy of enhanced disinfection and 
confi rms that the contaminated hospital environment is a 
modifi able risk factor.
Implications of all the available evidence
Multidrug-resistant organisms and C diffi  cile lead to adverse 
patient outcomes. Novel and improved prevention strategies 
are needed. Prevention of the spread of these organisms will 
probably require a multifaceted approach, including enhanced 
disinfection, improved hand hygiene, and antimicrobial 
stewardship. 
See Online for appendix
protocols, and UV-C device. The appendix provides 
information on standardisation of disinfection practices, 
implementation, and measures of protocol fi delity 
(appendix pp 1–2).
We did a microbiological analysis of 92 randomly 
selected seed rooms at two study hospitals to determine 
the total and average number of colony-forming units of 
the four target organisms that remained in the hospital 
room after terminal room disinfection (appendix p 4). 
Microbiological analyses and identifi cation were done 
with standard protocols.10 All hospitals used PCR-based 
nucleic acid amplifi cation tests to identify C diffi  cile 
throughout the study.
We designed this study to detect infection or 
colonisation with one of four target organisms: MRSA, 
VRE, C diffi  cile, or multidrug-resistant Acinetobacter.11 A 
seed room was defi ned as a room containing a patient 
with microbiologically proven current or history of 
infection or colonisation with one or more target 
organisms. History of infection or colonisation was 
defi ned as any positive culture within the 12 months 
before admission. The next patient admitted to the seed 
room was an exposed patient. Community-onset was 
defi ned as the isolation of a target organism within the 
fi rst 48 h of hospital admission. Hospital-acquired was 
defi ned as the isolation of a target organism after 48 h of 
hospital admission.
Outcomes
We had two primary outcomes: fi rst, the incidence of all 
target organisms among patients exposed to seed rooms, 
and second, the incidence of C diffi  cile infection among 
patients exposed to seed rooms, in the intention-to-treat 
population. Secondary outcomes were incidence among 
exposed patients of MRSA, of VRE, and of multidrug-
resistant Acinetobacter; incidence in the whole hospital of 
all target organisms, of MRSA, of VRE, of C diffi  cile, and of 
multidrug-resistant Acinetobacter; and adverse events (rate 
of UV-C device failure, time on diversion, emergency 
room wait time, health-care worker perception of cleaning 
methods, and room turnover time [time between patient 
discharge and completion of terminal room disinfection]; 
appendix pp 4–5). Incidence was calculated as the number 
of qualifying incident cases per 10 000 exposure days. 
Exposure days were calculated as the number of days the 
exposed patient spent in the seed room. Patients excluded 
from the numerator were also excluded from the 
denominator. Adverse outcomes were assessed at the 
hospital-level (ie, all patients or rooms were included in 
the analyses unless otherwise stated).
Three additional predetermined variables were 
measured at each study hospital: hand hygiene 
compliance, room cleaning compliance, and colonisation 
pressure (appendix pp 10–11).12 We obtained demographic 
data and comorbid conditions for all exposed patients 
314 819 patients with 606 811 room 
stays in nine hospitals 
31 226 room stays where patients 
were exposed 
575 585 rooms not exposed 
including wash-in periods
7112 exposed patients in 
 reference group
2196 excluded





4916 eligible for intention-to-
treat analysis
4916 eligible for per-protocol 
analysis
7577 exposed patients in UV 
group
2399 excluded





5178 eligible for intention-to-
treat analysis
2330 without documented 
use of UV machine
2848 eligible for per-protocol 
analysis
7893 exposed patients in bleach 
group
2455 excluded





5438 eligible for intention-to-
treat analysis
5438 eligible for per-protocol 
analysis
8644 exposed patients in bleach 
and UV group
2781 excluded





5863 eligible for intention-to-
treat analysis
2162 without documented 
use of UV machine
3701 eligible for per-protocol 
analysis
Figure: Trial profi le 
through administrative databases to calculate Charlson 
scores.13
We did two post-hoc analyses: (1) of the incidence of 
target organisms among exposed patients after removing 
the criteria requiring a minimum of 24 h in the seed 
room; and (2) of the incidence of target organisms due to 
vegetative bacteria (MRSA, VRE, and multidrug-resistant 
Acinetobacter; appendix p 4).
Exposed patients qualifi ed as an incident case of 
acquisition14 if they met the following criteria: in a seed 
room for 24 h or more AND a positive clinical culture 
or test with one of the target organisms AND the 
organism identifi ed in the clinical culture or test was 
the same target organism isolated from the preceding 
patient in the seed room AND the positive culture or 
test was obtained during the index admission either 
during exposure to the seed room OR the positive 
culture or test was obtained after exposure to the seed 
room during the index admission or readmission 
within 90 days of discharge from the room for MRSA, 
VRE, and multidrug-resistant Acinetobacter15 or within 
28 days of discharge from the room for C diffi  cile.16 We 
excluded incident cases if they were community-onset 
infections or the exposed patient had a microbiologically 
proven history of infection or colonisation with the 
same target organism during the 12 months before 
admission.
Statistical analysis
We did power calculations based on a review of 4 years of 
surveillance data from study hospitals and published 
literature. All power calculations were done with two-
sided signifi cance level of 0·05. We projected that 
1·96 million patient-days of care would be provided at the 
nine study hospitals (after excluding the wash-in periods). 
For each 6-month intervention period, we projected that 
approximately 491 200 patient-days of care would occur 
(distributed across nine participating hospitals). Based on 
data from our pre-existing surveillance databases, we 
projected that 959 outcomes due to the four target 
organisms would occur during the baseline (or reference) 
6-month period (ie, with standard terminal room
disinfection and no use of UV-C), for a baseline incidence
of 1·95 per 1000 patient-days. Under these assumptions,
the study would have 60% power to detect a 10% decrease
in incidence rate, 92% power to detect a 15% decrease,
and more than 99% power to detect a 20% decrease. The
power analysis was done using simulation and was
based on a Poisson regression model with hospital-level
incidence rate as the outcome and disinfection strategy
and hospital as the covariates.
All qualifying incident cases were included in the 
intention-to-treat population. The per-protocol population 
was identical to the intention-to-treat population for the 
reference strategy and bleach strategy. For the two 
strategies involving the UV device, the per-protocol 
population included qualifying incident cases who 
entered a seed room with documented use of the UV 
device. For the purposes of this study, the UV device only 
had to be turned on, the cycle did not have to be 
completed. The appendix contains a more detailed 
discussion of the diff erences between the analysis 
populations (pp 2–3).
We summarised patient characteristics using per-
centages for categorical variables and medians for con-
tinuous variables. We analysed outcomes using 
intention-to-treat and per-protocol principles for out-
comes among exposed patients. We analysed incidence 







Bleach and UV group 
(n=5863)
Demographics*
Mean age (SD) 57·9 (20·9) 58·5 (21·3) 58·6 (20·7) 57·7 (21·8)
Race
White 3042 (63%) 3228 (65%) 3416 (64%) 3747 (64%)
African American 1418 (30%) 1411 (28%) 1591 (30%) 1655 (28%)
Other 243 (5%) 233 (5%) 249 (5%) 329 (6%)
Unknown 102 (2%) 97 (2%) 95 (2%) 111 (2%)
Male sex 2475 (51%) 2518 (51%) 2768 (52%) 3017 (52%)
Comorbidities*
Median Charlson index (IQR) 2 (1–4) 2 (0–4) 2 (1–4) 2 (0–4)
Myocardial infarction 499 (11%) 457 (10%) 475 (9%) 583 (10%)
Congestive heart failure 937 (20%) 950 (20%) 1014 (20%) 1151 (21%)
Cerebrovascular disease 571 (12%) 540 (11%) 582 (11%) 610 (11%)
Hemiplegia or paraplegia 97 (2%) 118 (2%) 139 (3%) 166 (3%)
Peripheral vascular disease 450 (10%) 498 (10%) 524 (10%) 543 (10%)
Dementia 75 (2%) 101 (2%) 138 (3%) 111 (2%)
COPD 1248 (27%) 1325 (28%) 1339 (26%) 1516 (27%)
Rheumatic disease 161 (3%) 181 (4%) 183 (4%) 224 (4%)
Peptic ulcer disease 143 (3%) 97 (2%) 126 (2%) 178 (3%)
Liver disease
Mild 475 (10%) 452 (9%) 484 (9%) 557 (10%)
Moderate or severe 120 (3%) 142 (3%) 135 (3%) 177 (3%)
Diabetes mellitus 1302 (28%) 1248 (26%) 1371 (27%) 1505 (27%)
Complicated 303 (7%) 273 (6%) 350 (7%) 350 (6%)
Renal disease 980 (21%) 986 (21%) 1083 (21%) 1171 (21%)
Malignancy 842 (18%) 807 (17%) 864 (17%) 961 (17%)
Metastatic solid tumour 305 (7%) 340 (7%) 330 (6%) 367 (7%)
AIDS/HIV 49 (1%) 48 (1%) 52 (1%) 55 (1%)
Arrhythmia 1542 (33%) 1425 (30%) 1513 (30%) 1824 (33%)
Valvular heart disease 420 (9%) 415 (9%) 412 (8%) 566 (10%)
Pulmonary circulation 
disease
386 (8%) 452 (9%) 439 (9%) 495 (9%)
Hypertension 2264 (49%) 2237 (47%) 2336 (46%) 2709 (48%)
Complicated 826 (18%) 839 (18%) 959 (19%) 1007 (18%)
Other neurological disease 682 (15%) 665 (14%) 671 (13%) 792 (14%)
Hypothyroid disease 523 (11%) 545 (11%) 599 (12%) 637 (11%)
Data are n (%) unless stated otherwise. *The majority of patient-specifi c data were not available from one study 
hospital because of changes in electronic health record systems as follows: age (406 had data missing), race 
(428 missing), sex (407 missing), comorbidity data (1267 missing). COPD=chronic obstructive pulmonary disease. 
Table 1: Baseline characteristics
disinfection group (reference, UV, bleach, and bleach 
and UV), order of the strategies within the study (whether 
a particular strategy was used in the fi rst, second, third, 
or fourth study period), and hospital as fi xed-eff ect 
categorical covariates. We used generalised estimating 
equations to account for correlation between diff erent 
study strategies within the same hospital. Each of the 
study groups was compared to the reference group except 
for the analysis of C diffi  cile among exposed patients. 
Because this comparison involved the comparison of 
bleach vs bleach and UV-C, results from the UV group 
and the bleach and UV group were compared to results 
from the reference group and the bleach group. We used 
the same model construction strategy for all outcome 
analyses. We calculated relative risk (RR), 95% CIs, and 
risk reductions for each model. Statistical tests were 
done at a two-sided signifi cance level of 0·05. In light of 
the pragmatic nature of the trial, we made no adjustments 
for multiple comparisons. We did all statistical analyses 
using SAS (version 9.4).
The study is registered on ClinicalTrials.gov 
(NCT01579370).
Role of the funding source
The funder served an advisory role in the development of 
the study protocol. All authors had full access to all data 
in the study and had fi nal responsibility for the decision 
to submit for publication.
Results
All nine hospitals participated in the study from 
April, 2012, to July, 2014. The appendix shows the 
Reference UV group Bleach group Bleach and UV group
All target organisms
Exposed patients 4916 5178 5438 5863
Incident cases (%) 115 (2·3%) 76 (1·5%) 101 (1·9%) 131 (2·2%)
Exposure days 22 426 22 389 24 261 28 757
Rate (per 10 000 exposure-days) 51·3 33·9 41·6 45·6
Risk reduction (95% CI) Reference 17·4 (5·8 to 28·9) 9·7 (–2·7 to 22·0) 5·7 (–6·2 to 17·7)
RR (95% CI); p value Reference 0·70 (0·50 to 0·98); 0·036 0·85 (0·69 to 1·04); 0·116 0·91 (0·76 to 1·09); 0·303
Clostridium diffi  cile*
Exposed patients ·· ·· 2499 2678
Incident cases (%) ·· ·· 36 (1·4%) 38 (1·4%)
Exposure days ·· ·· 11 385 12 509
Rate (per 10 000 exposure-days) ·· ·· 31·6 30·4
Risk reduction (95% CI) ·· ·· Reference 1·2 (–12·7 to 15·2)
RR (95% CI); p value ·· ·· Reference 1·0 (0·57 to 1·75); 0·997
Meticillin-resistant Staphylococcus aureus
Exposed patients 3300 3451 3631 3848
Incident cases (%) 73 (2·2%) 54 (1·6) 74 (2·0) 89 (2·3)
Exposure days 14 524 14 780 15 343 18 960
Rate (per 10 000 exposure-days) 50·3 36·5 48·2 46·9
Risk reduction (95% CI) Reference 13·8 (0·1 to 27·3) 2·1 (–13·8 to 17·8) 3·4 (–8·9 to 15·5)
RR (95% CI); p value Reference 0·78 (0·58 to 1·05); 0·104 1·00 (0·82 to 1·21); 0·967 0·97 (0·78 to 1·22); 0·819
Vancomycin-resistant enterococci
Exposed patients 1055 1206 1468 1753
Incident cases (%) 37 (3·5%) 17 (1·4%) 24 (1·6%) 37 (2·1%)
Exposure days 5838 5780 7522 9488
Rate (per 10 000 exposure-days) 63·4 29·4 31·9 39·0
Risk reduction (95% CI) Reference 34·0 (9·3 to 58·6) 31·5 (12·7 to 50·2) 24·4 (0·5 to 48·2)
RR (95% CI); p-value Reference 0·41 (0·15 to 1·13); 0·084 0·43 (0·19 to 1·00); 0·049 0·36 (0·18 to 0·70); 0·003
Multidrug-resistant Acinetobacter†
Exposed patients 31 47 28 62
Incident cases (%) 0 0 1 (3·6) 0
Exposure days 156 199 98 244
Rate (per 10 000 exposure-days) 0 0 102·4 0
RR=relative risk. *Rooms with patients known or suspected of having C diffi  cile infection were terminally cleaned with bleach-containing solutions in all study disinfection 
strategies. †We created no models for multidrug-resistant Acinetobacter because only one outcome occurred in the nine study hospitals across all four study groups. 
Table 2: Results of intention-to-treat analysis
randomised assignment for each hospital (p 13). The 
average cluster size was 7807 (SD 644) patients. 
31 226 patients were exposed to a seed room; 24 585 (79%) 
stayed in the seed room for 24 h or more, and 21 395 (69%) 
met all inclusion criteria (fi gure). Baseline characteristics 
of qualifying exposed patients were similar for all four 
cleaning strategies (table 1).
A total of 423 outcomes were recorded: 228 (54%) 
cultures represented infection and 195 (46%) represented 
colonisation. 115 patients had a primary outcome during 
22 426 exposure days during the reference period 
(51·3 per 10 000 exposure days); the median incidence of 
target organisms in the baseline period per hospital was 
37·1 per 10 000 exposure days (range 17·5–101·6). The 
addition of a UV-C device to the standard disinfection 
strategy signifi cantly decreased the incidence of target 
organisms to 33·9 per 10 000 exposure-days (n=76; 
RR 0·70, 95% CI 0·50–0·98; p=0·036; table 2; appendix 
p 14). The incidence of target organisms was lower in 
eight of the nine study hospitals in the UV group 
(appendix p 15).
There was no signifi cant diff erence in the incidence of 
target organisms from rooms treated with bleach 
compared with reference (table 2). Similarly, there was 
no signifi cant diff erence between use of bleach and UV 
compared with reference (table 2). The appendix shows 
outcomes from individual study hospitals by intention to 
treat for each disinfection strategy (p 7).
The incidence of C diffi  cile was not signifi cantly diff erent 
with or without UV-C devices (table 2). The incidence of 
MRSA was not signifi cantly lower in the UV group and 
essentially unchanged in the bleach and bleach and UV 
groups (table 2). The incidence of VRE was not signifi cantly 
lower in the UV group but was signifi cantly lower in both 
groups that used a bleach-containing disinfectant (table 2). 
The use of bleach decreased the incidence of VRE by 57% 
Reference group UV group Bleach group Bleach and UV group
All target organisms
Exposed patients 4916 2848 5438 3701
Incident cases (%) 115 (2·3%) 46 (1·6%) 101 (1·9%) 93 (2·5%)
Exposure days 22 426 12 299 24 261 17 354
Rate (per 10 000 exposure-days) 51·3 37·4 41·6 53·6
Risk reduction (95% CI) Reference 13·9 (–0·1 to 27·9) 9·7 (–2·7 to 22·0) –2·3 (–15·7 to 11·1)
RR (95% CI); p value Reference 0·69 (0·50 to 0·95); 0·025 0·74 (0·61 to 0·91); 0·004 1·0 (0·81 to 1·23); 1·00
Clostridium diffi  cile*
Exposed patients ·· ·· 2499 1712
Incident cases (%) ·· ·· 36 (1·4%) 30 (1·8%)
Exposure days ·· ·· 11 385 8015
Rate (per 10 000 exposure-days) ·· ·· 31·6 37·4
Risk reduction (95% CI) ·· ·· Reference –5·8 (–17·1 to 5·5)
RR (95% CI); p value ·· ·· Reference 1·22 (0·68 to 2·17); 0·511
Meticillin-resistant Staphylococcus aureus
Exposed patients 3300 1872 3631 2425
Incident cases (%) 73 (2·2%) 28 (1·5%) 74 (2·0%) 63 (2·6%)
Exposure days 14 525 7934 15 343 10 681
Rate (per 10 000 exposure-days) 50·3 35·3 48·2 59·0
Risk reduction (95% CI) Reference 15·0 (–0·6 to 30·6) 2·1 (–13·8 to 17·8) –8·7 (–18·0 to 0·5)
RR (95% CI); p value Reference 0·67 (0·48 to 0·94); 0·019 0·89 (0·72 to 1·09); 0·260 1·09 (0·85 to 1·39); 0·503
Vancomycin-resistant enterococci
Exposed patients 1055 659 1468 1134
Incident cases (%) 37 (3·5%) 13 (2·0%) 24 (1·6%) 24 (2·1%)
Exposure days 5838 3265 7522 6237
Rate (per 10 000 exposure-days) 63·4 39·8 31·9 38·5
Risk reduction (95% CI) Reference 23·6 (–6·1 to 53·2) 31·5 (12·7 to 50·2) 24·9 (–0·6 to 50·4)
RR (95% CI); p value Reference 0·56 (0·21 to 1·50); 0·248 0·35 (0·16 to 0·78); 0·010 0·41 (0·22 to 0·77); 0·006
Data are unchanged for multidrug-resistant Acinetobacter baumaunii (table 2). *Rooms with patients known or suspected of having C diffi  cile infection were terminally cleaned 
with hypochlorite-containing solutions. 
Table 3: Results of per-protocol analysis
 
compared to reference; the use of bleach and a UV-C 
device decreased incidence of VRE by 64% (table 2). Only 
one patient acquired multidrug-resistant Acinetobacter 
after exposure in a seed room. Thus, no comparisons or 
models were constructed for this organism.
2848 (55%) of 5178 eligible rooms in the UV group and 
3701 (63%) of 5863 eligible of rooms in the bleach and UV 
group were included in the per-protocol analyses. Eff ect 
estimates were generally similar in per-protocol analyses 
to the intention-to-treat analyses (table 3). The incidence 
of MRSA, however, was signifi cantly lower in the UV 
group compared with the reference group (table 3).
Our microbiological assessment of 92 seed rooms after 
terminal disinfection showed that all enhanced strategies 
decreased the bioburden of target organisms, but the 
largest decrease occurred in the UV group (table 4). 
Protocol compliance, hand hygiene compliance, cleaning 
compliance, and colonisation pressure were similar 
across study groups (table 5; appendix p 4).
The median room cleaning time was approximately 
4 min longer in the UV and UV and bleach groups 
(table 5). The total wait time in the emergency department 
and days on diversion were unchanged across 
disinfection strategies. Time from admit decision to 
departure from the emergency department was
approximately 10–20 min longer in each of the enhanced 
disinfection groups compared with the reference group. 
One hospital reported a single UV-C exposure event 
during the study (appendix p 5). Additional secondary 
analyses, including incidence in the whole hospital of all 
target organisms, of MRSA, of VRE, of C diffi  cile, and of 
multidrug-resistant Acinetobacter, and health-care worker 
perception of cleaning methods, will be presented 
elsewhere.
We did two post-hoc analyses (appendix p 9). First, 
removing the 24-h exposure requirement for exposed 
patients did not change the eff ect measures. Second, 
after excluding patients admitted to C diffi  cile seed rooms, 
the decrease in incidence of target vegetative multidrug-
resistant organisms was strengthened in the UV group 
and signifi cantly lower in the bleach and UV group.
Discussion
Our large, prospective, multicentre, cluster-randomised 
trial is the fi rst, to our knowledge, to demonstrate a 
decrease in acquisition and infection with epidemio-
logically important pathogens following the use of 
enhanced room disinfection strategies. Patients admitted 
to rooms previously occupied by patients harbouring a 
multidrug-resistant organism or C diffi  cile were 10–30% 
less likely to acquire the same organism if the room was 
terminally disinfected using an enhanced strategy. The 
largest risk reduction occurred when a UV-C device was 
added to the standard disinfectant strategy. By contrast, 
we showed no statistically signifi cant decrease in 
outcomes when we used enhanced terminal disinfection 
with bleach or bleach and UV. Similarly, the incidence of 
C diffi  cile infection was not diff erent among exposed 
patients after adding UV to bleach disinfection.
Our results need to be interpreted in the appropriate 
context. First, decreases in acquisition of target 
organisms associated with the use of enhanced dis-
infection strategies were recorded even though our 
reference group was also an enhanced strategy of sorts. 
Overall compliance with thoroughness of cleaning in the 
reference group was roughly 90%. By contrast, most 
previous studies conclude that approximately half of all 
hospital room surfaces are not cleaned during terminal 
cleaning.4 Improved cleaning compliance decreases 
environmental bioburden17 and risk of acquisition, 
particularly of MRSA and VRE.18,19 Second, in the 
reference group, the quaternary ammonium-containing 
disinfectant was delivered with microfi bre cloths, which 
remove more bacteria than cotton and synthetic fi bre 
cloths.20 Third, the enhanced nature of the reference 
group and lack of multidrug-resistant Acinetobacter 
outcomes probably led to a decrease in power. Thus, the 
absence of a decrease in the incidence of target organisms 
among exposed patients in the bleach and bleach and UV 
groups might have been related to type II error.
No randomised controlled trials have previously been 
done using a UV device or enhanced chemical dis infectant. 
To our knowledge, only one other randomised controlled 
trial has investigated an enhanced terminal room 
disinfection strategy. A hydrogen peroxide vapour system 
was evaluated over 30 months in six high-risk units in a 
single tertiary care centre.21 Patients in intervention units 
had a 64% decrease in acquisition of multidrug-resistant 
organisms and C diffi  cile and a 75% decrease in acquisition 
of VRE compared to patients in control units.
UV devices reduce the environmental bioburden of 
MRSA, VRE, C diffi  cile, and Acinetobacter spp.10,22 Of four 
published studies on the clinical eff ectiveness of UV 
devices, one showed a 20% decrease in hospital-acquired 
multidrug-resistant organisms23 and three showed 































79 3·8 (14·2) 80 2·9 (12·6) 103 4·5 (14·5) 65 3·3 (10·4)
MRSA 179 8·5 (27·1) 3 0·1 (0·6) 101 4·4 (15·0) 17 0·9 (2·5)
VRE 831 39·6 (127·5) 6 0·2 (0·8) 56 2·4 (5·6) 38 1·9 (6·1)
MDR 
Acinetobacter spp
188 9·0 (36·4) 5 0·2 (0·9) 9 0·4 (1·9) 5 0·3 (0·9)
Total target 
organisms
1277 60·8 (161·3) 94 3·4 (13·4) 269 11·7 (21·4) 125 6·3 (16·1)
MRSA=meticillin-resistant Staphylococcus aureus. VRE=vancomycin-resistant enterococci. MDR=multidrug-resistant. 
CFU=colony-forming units. 
Table 4: Microbiological assessment
these results, we were surprised by the lack of change in 
rates of C diffi  cile among exposed patients. This lack of 
change might have been caused by the following factors. 
First, the reference group for our C diffi  cile-specifi c outcome 
involved the use of bleach. As we had high (around 90%) 
compliance with the use of bleach, there may have been 
relatively few residual spores for the UV device to 
eliminate.17 Second, UV is less eff ective against C diffi  cile 
than against vegetative bacteria, especially in areas of 
shadow.10,22 Third, we used a single-stage cycle with the 
UV-C device placed adjacent to but outside of the 
bathroom.27 Thus, we may not have eff ectively eliminated 
C diffi  cile from bathrooms. Finally, the environment might 
not play as large a role in C diffi  cile transmission as 
previously suspected.28 Eyre and colleagues29 assessed 
1250 cases of symptomatic C diffi  cile in Oxfordshire, UK, 
over a 4-year period using whole genome sequencing and 
reported that 45% of C diffi  cile cases were genetically 
distinct from previous cases. Although this analysis did not 
consider asymptomatic colonisation, only 2% of patients 
with related C diffi  cile isolates were linked by possible 
environmental con tamination. Our post-hoc analysis 
excluding patients exposed to C diffi  cile showed that the 
eff ect in the UV group was strengthened and the eff ect in 
the bleach and UV group became statistically signifi cant.
To our knowledge, no other randomised controlled 
trials have assessed the eff ect of using a sporicidal 
disinfectant on the incidence of our target organisms. 
Grabsch and colleagues30 recorded a 67% decrease in 
acquisition of VRE and an 83% decrease in VRE 
Reference UV group Bleach group Bleach and UV group
Hospital-level variables
Hand hygiene compliance
Observations 59 519 64 810 64 950 57 650
Median per hospital (IQR) 89·7 (86·3–94·7) 88·1 (84·6–95·7) 91·4 (86·2–96·1) 90·8 (82·8–94·1)
Room cleaning
Room observations 5717 4312 4538 5869
Mean number of locations 
monitored per room
12·4 11·6 12·5 12·0
Locations monitored 70 704 50 081 56 753 70 312
Median compliance (IQR) 100% (91–100) 95% (86–100) 100% (87–100) 100% (84–100)
Median colonisation pressure (IQR) 4·6% (3·1–9·7) 4·3% (3·6–6·6) 4·5% (3·7–5·8) 4·8% (3·4–6·7)
Protocol compliance
pH pen use (%) 4836/5024 (96%) 2970/3262 (91%) 1161/1206 (96%) 5899/6002 (98%)
Median (IQR) 100 (91–100) 93 (89–97) 96 (95–98) 99 (97–99)
UV-C devices used in contact 
precaution rooms (%) ·· 6214/7137 (87%) ·· 10 006/11 274 (89%)
Median (IQR) ·· 92 (85–93) ·· 91 (87–91)
Adverse events
Room turnover times
Median total turnover time (IQR) 79·4 (74·4–117·3) 88·9 (80·0–93·4) 82·6 (73·1–123·3) 87·5 (76·2–127·0)
Rooms 78 413 127 028 114 101 102 227
Median room cleaning time (IQR) 35·9 (32·5–38·5) 40·7 (38·4–42·1) 35·6 (32·3–38·9) 40·1 (39·1–44·2)
Rooms 133 744 144 183 132 753 137 814
Emergency department waiting times 
(min)
Median total time in emergency 
department (range; n=7)
392 (290–537) 390 (286–534) 392 (290–533) 399 (294–544)
Observations 34 532 31 961 30 613 32 320
Median time from admit decision 
to departure from emergency 
department (range; n=4)
92 (64–135) 110 (72–180) 116 (75–194) 108 (70–184)
Observations 18 443 24 025 21 566 23 732
Time on diversion (days)
Total 63·8 53·8 34·2 38·2
Median per hospital (IQR) 2·7 (0·3–11·7) 2·5 (1·7–7) 2·9 (0·6–7·5) 1·3 (0·6–6·6)
Table 5: Hospital outcomes
bacteraemia with use of bleach. Results from the 
intention-to-treat analysis in our trial did not show a 
signifi cant decrease in the incidence of target organisms 
following the routine use of bleach for terminal 
disinfection of contact precaution rooms. Results from a 
prespecifi ed secondary analysis, however, validate the 
decrease in VRE reported by Grabsch and colleagues. 
Our clinical results were largely corroborated by our 
microbiological assessment of seed rooms after terminal 
disinfection; greater reductions in colony-forming units 
occurred in the UV group than in the bleach and UV and 
bleach groups.
Our study has limitations. First, we relied on clinical 
cultures obtained during the course of standard care, 
which might have introduced ascertainment bias. 
Clinicians might have changed their culturing practices 
during the course of the study. Additionally, because we 
did not screen seed patients with a history of infection or 
colonisation or all exposed patients on exit from the seed 
rooms, we did not capture all acquisitions, might have 
failed to exclude a patient with community-onset 
colonisation, and our denominators might have included 
extra exposure days. We doubt, however, that any of these 
scenarios aff ected our results given randomisation. 
Second, we did not do molecular analyses to confi rm that 
the organisms included in our outcomes were related to 
organisms in the environment, as this task was impossible 
given the scope of our study. Third, we did not account for 
multiplicity in our statistical testing given the pragmatic 
nature of our study; thus, the p values generated from our 
analyses should be interpreted with caution. Fourth, as 
noted above, our study had an enhanced reference group 
and thus decreased power. As a result, we suspect the 
eff ect measures in our study represent minimum eff ects 
of these strategies. Finally, our intervention was directed 
towards three multidrug-resistant organisms and C diffi  cile. 
We suspect that enhanced terminal room disinfection 
strategies decrease risk of acquisition of non-multidrug-
resistant organisms, such as meticillin-susceptible S aureus 
and vancomycin-susceptible enterococci.
Acquisition and infection with multidrug-resistant 
organisms and C diffi  cile in health care is a complex and 
multi faceted process. Our study suggests that (1) the 
health-care environment is an important source for 
acquisition of multidrug-resistant organisms and 
C diffi  cile, and (2) the risk of acquisition of these patho-
gens from the environment can be modifi ed. More than 
a century after Semmelweis and Lister’s landmark 
studies, our results suggest that methods to improve 
disinfection can still lead to better patient outcomes.
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